Sort by
Refine Your Search
-
Listed
-
Country
-
Employer
- Nature Careers
- The Ohio State University
- Duke University
- FAPESP - São Paulo Research Foundation
- Rutgers University
- University of London
- University of Luxembourg
- University of Maryland, Baltimore
- University of Oslo
- CNRS
- Chalmers University of Technology
- Duke University Medical Center
- Institut Pasteur
- Institute of Physical Chemistry, Polish Academy of Sciences
- Johns Hopkins University
- KU LEUVEN
- Karolinska Institutet (KI)
- King's College London
- Lunds universitet
- MOHAMMED VI POLYTECHNIC UNIVERSITY
- Medical Research Council
- Montana State University
- SUNY University at Buffalo
- Saint Louis University
- SciLifeLab
- Stanford University
- Technical University of Denmark
- The University of North Carolina at Chapel Hill
- Umeå universitet stipendiemodul
- University of Basel
- University of California, Los Angeles
- University of Colorado
- University of Florida
- University of Lund
- University of Miami
- University of North Carolina at Chapel Hill
- University of Oxford
- University of Sydney
- University of Texas at Dallas
- University of Washington
- VIB
- Washington State University
- 32 more »
- « less
-
Field
-
antibody specificity profiling. KEY RESPONSIBILITIES You’ll join a small team advancing a new screening platform focused on therapeutic antibody specificity. The aim is to deploy this newly developed assay
-
), potentially through antibody-dependent cellular cytotoxicity (ADCC). This project aims to investigate the pathophysiological role of CD8 TEMRA-mediated ADCC in individuals at the prodromal stage of PD
-
which small-molecule inhibitors and therapeutic antibodies modulate autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease. Responsibilities include designing and performing
-
monoclonal antibodies Generation of B-cell receptor transduced cell lines Antibody-antigen binding studies Targeting of B cells in in vitro assays Writing of scientific papers and presentation of results
-
) - Łukasiewicz Research Network - PORT Polish Center for Technology Development, Co-Financed by the Polish Science Fund, project no. WIB-4/2024-O04, entitled “Personalized antibody–drug conjugates activated by
-
the development and characterization of antibodies, antibody-drug conjugates, bispecific antibodies, or cell-based immunotherapies (e.g., CAR-T or CAR-NK). Experience in advanced molecular and cellular biology
-
The University of North Carolina at Chapel Hill | Chapel Hill, North Carolina | United States | about 1 month ago
mechanisms of tolerance-induction by antibody-based and microparticle-based antigen-specific immunotherapies for the prevention and reversal of T1D. The work is supported by numerous state-of-the-art Core
-
experimental approaches for structural biology (e.g., cryo-electron microscopy/tomography, X-ray crystallography) is a significant plus. Experience with antibody engineering (e.g., expression, stability, binding
-
, cryosectioning, immunocytochemistry/immunohistochemistry, advanced staining (antibodies, RNAscope, proximity ligation assays) and high-resolution imaging approaches and quantifications from both mouse and human
-
the molecular mechanisms of bacterial virulence factors and translating these discoveries into macromolecular drug development—specifically focusing on antibodies, vaccines, and innovative medical cosmetics